Nerviano Medical Sciences   Report issue

For profit Phase 1 Phase 2
Founded: Nerviano Italy (2004)

Organization Overview

First Clinical Trial
2006
NCT01300468
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

CLIOSS (Nerviano Medical Sciences Group), Italy | Nerviano Medical Sciences

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Leukemia (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Leukemia, Myelomonocytic, Chronic (Phase 2)

Leukemia, Myelomonocytic, Juvenile (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasms (Phase 1)

Neoplasms, Plasma Cell (Phase 2)

Prostatic Neoplasms (Phase 2)

Thymoma (Phase 2)

Thymus Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 15
  • # of Trial APIs: 12